Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors
Total Page:16
File Type:pdf, Size:1020Kb
cancers Review Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors Gabriel LaPlante 1 and Wei Zhang 1,2,* 1 Department of Molecular and Cellular Biology, College of Biological Science, University of Guelph, 50 Stone Rd E, Guelph, ON N1G2W1, Canada; [email protected] 2 CIFAR Azrieli Global Scholars Program, Canadian Institute for Advanced Research, MaRS Centre West Tower, 661 University Avenue, Toronto, ON M5G1M1, Canada * Correspondence: [email protected] Simple Summary: The ubiquitin-proteasome system regulates multiple facets of protein homeostasis to modulate signal transduction in numerous biological processes. Not surprisingly, dysregulation of this delicately balanced system is frequently observed in cancer progression. In the past two decades, researchers in both academia and industry have made significant progress in developing small-molecule inhibitors targeting various components in the ubiquitin-proteasome system for cancer therapy. Here, we aim to provide a comprehensive summary of these efforts. Additionally, we overview the advancements of targeted protein degradation, a recently emerging drug discovery concept in cancer therapy. Abstract: The ubiquitin-proteasome system (UPS) is a critical regulator of cellular protein levels and activity. It is, therefore, not surprising that its dysregulation is implicated in numerous human diseases, including many types of cancer. Moreover, since cancer cells exhibit increased rates of protein turnover, their heightened dependence on the UPS makes it an attractive target for inhibition Citation: LaPlante, G.; Zhang, W. via targeted therapeutics. Indeed, the clinical application of proteasome inhibitors in treatment Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by of multiple myeloma has been very successful, stimulating the development of small-molecule Small-Molecule Inhibitors. Cancers inhibitors targeting other UPS components. On the other hand, while the discovery of potent and 2021, 13, 3079. https://doi.org/ selective chemical compounds can be both challenging and time consuming, the area of targeted 10.3390/cancers13123079 protein degradation through utilization of the UPS machinery has seen promising developments in recent years. The repertoire of proteolysis-targeting chimeras (PROTACs), which employ E3 ligases Academic Editors: Alberto Inga and for the degradation of cancer-related proteins via the proteasome, continues to grow. In this review, Lucília Saraiva we will provide a thorough overview of small-molecule UPS inhibitors and highlight advancements in the development of targeted protein degradation strategies for cancer therapeutics. Received: 27 May 2021 Accepted: 17 June 2021 Keywords: ubiquitin (Ub); ubiquitin-proteasome system (UPS); cancer; small-molecule; proteolysis- Published: 20 June 2021 targeting chimera (PROTAC); E3 ligase; deubiquitinase (DUB) Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affil- 1. Introduction iations. The ubiquitin-proteasome system (UPS) is vital for protein homeostasis and is im- plicated in many cellular processes, including DNA repair [1], endocytic trafficking [2], and the immune response [3]. The wide range of activities regulated by the UPS stems from the remarkable specificity and diversity of signal transduction events enabled by Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. the process of ubiquitination. Ubiquitination is a post-translational protein modification This article is an open access article involving the covalent attachment of ubiquitin (Ub), a highly conserved 76-amino acid distributed under the terms and polypeptide, to a substrate via the coordinated activities of a Ub-activating enzyme (E1), a conditions of the Creative Commons Ub-conjugating enzyme (E2), and a Ub ligase (E3) (Figure1)[ 4–6]. In the presence of ATP, Attribution (CC BY) license (https:// Ub is activated by E1 before being delivered to the E2 enzyme, and this is followed by its creativecommons.org/licenses/by/ eventual transfer to the substrate proteins, catalyzed by a E3 ligase [5,7]. Most commonly, 4.0/). Ub is reversibly conjugated either at a lysine (K) residue or an N-terminal amino acid Cancers 2021, 13, 3079. https://doi.org/10.3390/cancers13123079 https://www.mdpi.com/journal/cancers Cancers 2021, 13, x FOR PEER REVIEW 2 of 44 Cancers 2021, 13, 3079 2 of 43 Ub is reversibly conjugated either at a lysine (K) residue or an N-terminal amino acid and andcan canbe attached be attached as a single as a single polypeptide polypeptide (mono-ubiquitination) (mono-ubiquitination) or a polymer or a polymer of at least of four at least(poly-ubiquitination) four (poly-ubiquitination) [4,7–10]. Ub [4,7 itself–10]. cont Ub itselfains seven contains lysines, seven any lysines, of which any ofcan which be an canattachment be an attachment site for the site next for molecule the next moleculein a poly-Ub in achain. poly-Ub Additional chain. Additional layers of complexity layers of complexityarise by post-translational arise by post-translational modifications modifications and the addition and the additionof Ub-like of Ub-likemolecules, molecules, such as suchNEDD8, as NEDD8, to Ub chains to Ub [11]. chains The [11 resulting]. The resulting diverse diversepossibilities possibilities of mixed, of branched, mixed, branched, or mod- orified modified chains chainsprovides provides the basis the for basis the for functional the functional diversity diversity of Ub ofsignaling. Ub signaling. FigureFigure 1. 1.Overview Overview of of the the ubiquitin-proteasome ubiquitin-proteasome system system (UPS). (UPS). The The E1, E2,E1, E3E2, enzyme E3 enzyme cascade cascade results re- sults in the ubiquitination of a protein substrate. HECT and RBR-type E3 ligases perform a two-step in the ubiquitination of a protein substrate. HECT and RBR-type E3 ligases perform a two-step ubiquitination, whereas RING E3s perform direct Ub transfer. K48-linked poly-ubiquitination re- ubiquitination, whereas RING E3s perform direct Ub transfer. K48-linked poly-ubiquitination results sults in proteasomal degradation, whereby the 19S proteasomal subunit removes Ub moieties prior into proteasomal the substrate’s degradation, proteolytic wherebydegradation the by 19S the proteasomal 26S subunit. subunit DUBs can removes rescue Ub substrate moieties expression prior to theor substrate’salter cell signaling proteolytic by degradationremoving Ub by moieties. the 26S subunit.Ub, ubiquitin; DUBs canHECT, rescue Homologous substrate expression to E6-AP car- or alterboxyl cell terminus; signaling RBR, by removing RING-betw Ubeen-RING; moieties. Ub, RING, ubiquitin; really HECT,interesting Homologous new gene; to DUB, E6-AP deubiquiti- carboxyl terminus;nase. RBR, RING-between-RING; RING, really interesting new gene; DUB, deubiquitinase. TheThe eventual eventual fatefate ofof a a ubiquitinated ubiquitinated proteinprotein dependsdepends onon thethe naturenature ofof thethe UbUb chain.chain. TheThe most most well-studied well-studied linkage linkage is theis the K48-linked K48-linked polyubiquitination, polyubiquitination, which which generally generally targets tar- proteinsgets proteins for proteasomal for proteasomal degradation degradation [6]. The [6]. 26SThe proteasome 26S proteasome is a large is a large protein protein complex com- consistingplex consisting of the of 20S the catalytic20S catalytic core core and and 19S 19S regulatory regulatory subunit(s) subunit(s) [12 [12].]. The The 19S 19S subunit subunit cleavescleaves thethe Ub Ub moiety moiety from from the the protein protein substrate substrate and and threads threads the the unfolded unfolded protein protein into into thethe catalytic catalytic core, core, where where the the substrate substrate is is degraded degraded via via chymotrypsin-like, chymotrypsin-like, trypsin-like, trypsin-like, and and Cancers 2021, 13, 3079 3 of 43 caspase-like proteolysis activities [10,12,13]. The second-best understood linkage, K63, has important non-proteolytic roles, including functions in protein trafficking [2,14] and the DNA damage response pathways [1]. Importantly, K48 chains can also be involved in non- proteolytic functions, while K63 chains, conversely, have known proteolytic functions [7]. The other five lysine linkages (K6, K11, K27, K29, and K33) are less well-studied, although this topic has recently been comprehensively reviewed [15]. Briefly, K6-linked poly-Ub chains have been shown to be involved in autophagy and the DNA damage response; K11 chains are implicated in cell cycle regulation and proteasomal degradation or stabilization; K27 chains are important actors in the innate immune response; K29 chains are involved in cell signaling, with potentially protective roles in neurodegenerative diseases; and K33 chains have purported roles in cell signaling and protein trafficking. The diverse arsenal of Ub signals implies that Ub-interacting proteins must possess some means of deciphering the code, and indeed, the eukaryotic genome contains an array of Ub binding domains (UBDs) that can confer linkage specificity to a Ub receptor [16]. While many UBDs are promiscuous on their own, the structural environment created between the UBD and its surrounding domains, whether on the same protein or adjacent proteins within a complex, can confer remarkable selectivity [7]. While the specific mechanism of ubiquitination can vary, the process is generally catalyzed by the E1!E2!E3 signaling